<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683082</url>
  </required_header>
  <id_info>
    <org_study_id>803/2018</org_study_id>
    <nct_id>NCT03683082</nct_id>
  </id_info>
  <brief_title>Oxygen Treatment and Pulmonary Arterial Hypertension</brief_title>
  <official_title>Acute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Papanicolaou Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Papanicolaou Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary arterial hypertension (PAH) is a disease characterised with significant morbidity
      and poor prognosis. Dyspnoea and impaired exercise capacity are very common manifestations of
      the disease, and result in significant impairment of patients' quality of life. Although
      hypoxemia is common among subjects with PAH, published data on the effects of supplementary
      oxygen therapy on specific clinical outcomes among these patients are currently few, while
      the existing data on the potential benefits of oxygen supplementation to treat
      exercise-induced hypoxemia, in this patient population, are even more controversial. Based on
      the aforementioned, the purpose of this prospective, crossover clinical trial is to
      investigate the acute effects of supplemental oxygen administration on the: a) exercise
      capacity, b) severity of dyspnea, c) cerebral oxygenation, b) muscle oxygenation, and e)
      hemodynamic profile, as compared to delivery of medical air (sham oxygen), in a group of
      patients with PAH, during steady state cardiopulmonary exercise testing (CPET)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise duration</measure>
    <time_frame>through study completion, an average of a year</time_frame>
    <description>Exercise duration (minutes), while conducting steady state cardiopulmonary exercise testing until exhaustion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>through study completion, an average of a year</time_frame>
    <description>Maximum dyspnea assessed by Borg dyspnea scale, during steady state cardiopulmonary exercise testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral oxygenated hemoglobin</measure>
    <time_frame>through study completion, an average of a year</time_frame>
    <description>minimum value of cerebral oxygenated hemoglobin during steady state cardiopulmonary exercise testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>through study completion an average of a year</time_frame>
    <description>maximum cardiac output during steady state cardiopulmonary exercise testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>through study completion, an average of a year</time_frame>
    <description>Maximum fatigue as assessed by Borg fatigue scale, during steady state cardiopulmonary exercise testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>PAH patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAH patients (crossover)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen supplementation</intervention_name>
    <description>40% FiO2 via Venturi mask</description>
    <arm_group_label>PAH patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham O2 (medical air)</intervention_name>
    <description>Medical air supplementation via Venturi mask</description>
    <arm_group_label>PAH patients (crossover)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Group I PAH patients

          2. Stable disease (no hospitalisation, disease deterioration or change in regular PAH
             medication during the last month)

          3. Presence of exercise-induced hypoxemia

        Exclusion Criteria:

          1. Major contraindications for CPET conduction

          2. Not providing informed consent -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgia Pitsiou, MD, Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>&quot;G. Papanikolaou&quot; General Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afroditi Boutou, MD, PhD, MSc</last_name>
    <phone>00306946611433</phone>
    <email>afboutou@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>&quot;G. Papanikolaou&quot; General Hospital</name>
      <address>
        <city>Thessalon√≠ki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afroditi Boutou, MD, MSc, PhD</last_name>
      <phone>00306946611433</phone>
      <email>afboutou@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Papanicolaou Hospital</investigator_affiliation>
    <investigator_full_name>Afroditi Boutou</investigator_full_name>
    <investigator_title>Consultant in Respiratory Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

